Janelle Barowski, MSN RN

Researchers examined factors associated with antibiotic prescribing among older adults infected with COVID-19.

Researchers evaluated outcomes among patients with mild to moderate COVID-19 infection who received mAb treatment with casirivimab-imdevimab vs sotrovimab.

Researchers examined if positive and negative expectations prior to COVID-19 vaccination are associated with adverse effects after receipt of the second vaccine dose.

Researchers evaluated the incidence of occupational blood exposures and post-exposure prophylaxis completion rates among health care workers.

Researchers evaluated the risk for household COVID-19 transmission among adults and children with prior infection-induced immunity.

Researchers sought to assess the effectiveness of intravenous methylprednisolone vs intravenous immunoglobulins for treating PIMS-TS.

Researchers evaluated risk factors associated with persistent COVID-19 symptoms at 28 and 90 days following infection onset.

Researchers compared the risk for prolonged symptoms following COVID-19 infection among individuals infected during the pre-Delta, Delta, and Omicron periods.

Researchers evaluated the effectiveness and safety of COVID-19 vaccination during pregnancy.

Researchers evaluated national action plans on efforts to control antimicrobial resistance across 114 countries.

Researchers evaluated outcomes of partial-oral antibiotic therapy for the treatment of bone and joint infections in patients with recent injection drug use.

Sodium-glucose cotransporter-2 inhibitor use prior to the onset of COVID-19 infection was associated with the lowest risk for adverse outcomes in patients with diabetes.

Researchers evaluated the safety and efficacy of ensitrelvir for the treatment of mild to moderate COVID-19 infection during the Omicron wave.

Researchers evaluated the short-term safety profile of a second booster dose of a COVID-19 mRNA vaccine.

Researchers compared the presence of symptoms 2 years after acute COVID-19 infection between hospitalized and nonhospitalized patients.

Researchers evaluated the effectiveness of bivalent mRNA COVID-19 vaccination among adults who previously received at least 2 monovalent vaccine doses.